1H-Pyrimido[4,5-c][1,2]oxazine, 3,4-dihydro- | 259881-55-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1H-Pyrimido[4,5-c][1,2]oxazine, 3,4-dihydro-
• 英文别名: 3,4-dihydro-1H-pyrimido[4,5-c]oxazine
• CAS: 259881-55-5
• 化学式: C₆H₇N₃O
• mdl: MFCD18809886
• 分子量: 137.14
• InChiKey: OATGMUUQJINGAP-UHFFFAOYSA-N

物化性质

• 沸点：
  249.6±33.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE, COMPOSITIONS, KIT AND METHOD FOR TREATMENT OF AIRWAY DISORDERS ASSOCIATED WITH BRONCHOCONSTRICTION, LUNG INFLAMMATION, ALLERGY(IES) AND SURFACTANT DEPLETION
  申请人：East Carolina University

  公开号：EP1168919A2

  公开（公告）日：2002-01-09
• [EN] LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE, COMPOSITIONS, KIT AND METHOD FOR TREATMENT OF AIRWAY DISORDERS ASSOCIATED WITH BRONCHOCONSTRICTION, LUNG INFLAMMATION, ALLERGY(IES) AND SURFACTANT DEPLETION<br/>[FR] OLIGONUCLEOTIDE ANTISENS A FAIBLE TENEUR EN ADENOSINE, COMPOSITIONS, KIT ET PROCEDE POUR LE TRAITEMENT D'AFFECTIONS DES VOIES AERIENNES ASSOCIEES A LA BRONCHOCONSTRICTION, A L'INFLAMMATION PULMONAIRE, AUX ALLERGIES ET A LA DEPLETION DE SURFACTANT
  申请人：UNIV EAST CAROLINA

  公开号：WO2000062736A2

  公开（公告）日：2000-10-26

  An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA comprises the topical admistration, e.g. to the respiratory system, of a subject of a therapeutic amount of an oligonucleotide that is antisense to the initiation codon region, coding region, 5' or 3' inton-exon junctions or regions within 2 to 10 nucleotides of the junctions of the target gene, or antisense to a mRNA complementary to the target gene in an amount effective to reach the target polynucleotide and reducing or inhibiting expression. Additionally, a method of treating and adenosine mediated effect is described also utilizing the delivery of antisense and in order to minimize triggering adenosine receptors by their metabolism, the administered oligos have a low content of or are essentially free of adenosine. The agent, composition and formulations are used for prophlactic, preventive and therapeutic treatment of ailments associated with impaired respiration, lung allergies and/or vasoconstriction, inflammation, allergies, allergic rhynitis, asthma, impeded respiration, lung pain, cystic fibrosis and bronchoconstriction.
• [EN] COMPOSITION, FORMULATIONS & KITS FOR TREATMENT OF RESPIRATORY & LUNG DISEASE WITH ANTI-SENSE OLIGONUCLEOTIDES & A BRONCHODILATING AGENT<br/>[FR] COMPOSITION, PREPARATIONS ET TROUSSES POUR LE TRAITEMENT DE MALADIE RESPIRATOIRE ET PULMONAIRE AU MOYEN D'OLIGONUCLEOTIDES ANTISENS ET D'UN AGENT BRONCHODILATEUR
  申请人：EPIGENESIS PHARMACEUTICALS INC

  公开号：WO2002085309A2

  公开（公告）日：2002-10-31

  This patent relates to a composition comprising a carrier, oligonucleotides (oligos) that are anti-sense to adenosine receptors, and contain low amounts of or no adenosine (A), and bronchodilating agents. These agents and the composition and formulations provided are suitable for the treatment of respiratory tract, pulmonary and maliugnant diseases associated with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and composition may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, negative side effects.